Pharma DECODED
Latest edition: 10 May 2024
Share newsletter
Get the full version straight to your inbox.
Exclusive access to our best-in-class data & intelligence
Subscribe now
Spotlight
Takeda tackles $900m restructuring plan after generics hurt annual profits
Workforce optimisation, R&D prioritisation and technology investments are on Takeda’s agenda.
Latest news
Novo Nordisk enters deal to develop obesity therapy
The company may make upfront, development, and commercial milestone payments of $600m.
Marinus parts ways with 20% of its workforce
Marinus expects to share data from the Phase III RAISE trial of IV ganaxolone for the treatment of status epilepticus later in the summer.
Formosa and Tabuk sign deal for FDA-approved ophthalmic suspension
Clobetasol propionate ophthalmic suspension obtained FDA approval in March 2024.
Acumen doses first patient in Phase II Alzheimer's disease trial
ImmunoBrain Checkpoint Inc. (IBC), a biopharmaceutical company developing innovative disease-modifying immune therapies to combat neurodegenerative diseases, announced that it has dosed the first two patients in the Phase 1b IBC-01-01 clinical trial investigating IBC's lead program, IBC-Ab002 for patients with early Alzheimer's disease. IBC-Ab002 is a novel, fully human anti-PD-L1 monoclonal antibody designed to harness the peripheral immune system to help the brain overcome the multiple pathological factors that contribute to the cognitive manifestation and progression of neurodegenerative diseases, including local brain inflammation, amyloid beta, tau pathologies and neuronal loss.
Kite and Arcellx prepare to launch Phase III multiple myeloma trial
The Phase III trial of anito-cel for multiple myeloma is anticipated to begin in late 2024.
FDA ratifies CEL-SCI's confirmatory study plan for head and neck cancer therapy
Marking yet another chapter in approval pathway for Multikine, CEL-SCI has announced a confirmatory study with new inclusion criteria.
Innovent's mazdutide superior to Trulicity in Phase III T2D trial
Key secondary endpoints also showed mazdutide's superior benefits in both glucose-lowering and weight loss.
In our previous edition
Pharma Decoded
ESCMID 2024: Emerging bacterial infections in neonates and children
09 May 2024
Pharma Decoded
AstraZeneca to withdraw Covid-19 vaccine globally
08 May 2024
Pharma Decoded
BioNTech reports net loss of €315.1m in Q1 2024
07 May 2024
Still looking?
Search companies, themes, reports, as well as actionable data & insights spanning 22 global industries
Explorer
Access more premium companies when you subscribe to Explorer